Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients

Chinese Medical Journal

Volumn 125, Issue 20, 2012, Pages 3725-3729

  Yuan, Jia qi ^a   Xu, Tao ^a   Zhang, Xiao wei ^a   Yu, Lu ping ^a   Li, Qing ^a   Liu, Shi jun ^a   Huang, Xiao bo ^a   Wang, Xiao feng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Hormone therapy; Individualized medicine; Metabolic syndrome; Orchiectomy; Prostate cancer

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CASTRATION; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PROSTATE CANCER; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; ANDROGEN ANTAGONISTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM GRADING; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84867907923     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.20.023     Document Type: Article

References (21)

1. Ian LH, Li H, Yang Y, Ho CF. Comparisons of the incidence and pathological characteristics of prostate cancer between Chinese and Portuguese in Macau. Chin Med J 2008; 121: 292-294.
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240.
3. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93: 2042-2049.
4. Torimoto K, Samma S, Kagebayashi Y, Chihara Y, Tanaka N, Hirayama A, et al. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol 2011; 41: 577-581.
5. Reis C, Liberman S, Pompeo AC, Srougi M, Halpern A, Filho WJ. Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics (Sao Paulo) 2009; 64: 781-784.
6. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261-4267.
7. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 657-660.
8. Chen W, Lu F, Liu SJ, Du JB, Wang JM, Qian Y, et al. Cancer risk and key components of metabolic syndrome: a population-based prospective cohort study in Chinese. Chin Med J 2012; 125: 481-485.
9. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 2000; 85: 1069-1073.
10. Yamamoto S, Matsunaga N, Hitaka T, Yamada M, Hara T, Miyazaki J, et al. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists. Bioorg Med Chem 2012; 20: 422-434.
11. Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem 2011; 54: 7693-7704.
12. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985; 12 (1 Suppl 1): 28-35.
13. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004; 64: 765-771.
14. Galvão DA, Spry N, Taaffe DR, Denham J, Joseph D, Lamb DS, et al. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer 2009; 9: 419.
15. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010; 60: 194-201.
16. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46.
17. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-3983.
18. Yuan XD, Dong ZG, Zhang H, Lin HY, Song XH, Niu ZH, et al. Distribution of serum prostate-specific antigen in Chinese healthy men: a population-based study. Chin Med J 2011; 124: 1189-1192.
19. Zhao LP, Lü AK, Shen WF, Liu HF, Ma XY, Fan XM, et al. Influence of insulin resistance on long-term outcomes in patients. Chin Med J 2010; 123: 651-657.
20. Ji LN, Liu W, Liu W, Liu J, Dong YH, Wang CJ, et al. Impact of newly recommended HbA1c-based diabetes diagnostic criteria on the prevalence of diabetes and high risk individual in clinical and commonly population in China. Chin Med J 2010; 123: 1103-1104.
21. Ueshima H, Okayama A, Saitoh S, Nakagawa H, Rodriguez B, Sakata K, et al. Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study. J Hum Hypertens 2003; 17: 631-639.